Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAptamer Group Regulatory News (APTA)

Share Price Information for Aptamer Group (APTA)

Share Price is delayed by 15 minutes
Get Live Data
0.525    -0.025 (-4.55%)
Bid:
0.50
Ask:
0.55
Spread: 0.05 (10.00%)
Market Cap: £18.14m
APTA Live PriceLast checked at - London Stock Exchange

Intraday Aptamer Group Share Chart

TR-1

15 Aug 2023 17:43

RNS Number : 4199J
Aptamer Group PLC
15 August 2023
 

 

 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

APTAMER GROUP PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

X

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

Gresham House Asset Management Ltd

City and country of registered office (if applicable)

London, UK

4. Full name of shareholder(s) (if different from 3.) v

Name

Baronsmead Venture Trust plc

Baronsmead Second Venture Trust plc

City and country of registered office (if applicable)

London, UK

5. Date on which the threshold was crossed or reached vi:

04/08/2023

6. Date on which issuer notified (DD/MM/YYYY):

08/08/2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

4.95%

4.95%

3,927,555

Position of previous notification (if

applicable)

5.70%

5.70%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BNRRP542

3,927,555

4.95%

SUBTOTAL 8. A

3,927,555

4.95%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

X

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Baronsmead Venture Trust plc

Below 3%

Below 3%

Baronsmead Second Venture Trust plc

Below 3%

Below 3%

 

10. In case of proxy voting, please identify:

Name of the proxy holder

Gresham House Asset Management Ltd

The number and % of voting rights held

N/A

The date until which the voting rights will be held

N/A

11. Additional information xvi

 

Place of completion

Gresham House Asset Management Ltd

Date of completion

08/08/2023

 

 

 

 

Notes

 

i Please note this form should be read jointly with the applicable Disclosure Guidance and Transparency Rules Chapter 5 (DTR5) available on the following link: https://www.handbook.fca.org.uk/handbook/DTR/5/?view=chapter

 

ii Full name of the legal entity and further specification of the issuer or underlying issuer, provided it is reliable and accurate (e.g. address, LEI, domestic number identity). Indicate in the relevant section whether the issuer is a non UK issuer.

 

iii Other reason for the notification could be voluntary notifications, changes of attribution of the nature of the holding (e.g. expiring of financial instruments) or acting in concert.

 

iv This should be the full name of (a) the shareholder; (b) the natural person or legal entity acquiring, disposing of or exercising voting rights in the cases provided for in DTR5.2.1 (b) to (h); (c) all parties to the agreement referred to in DTR5.2.1 (a) or (d) the holder of financial instruments referred to in DTR5.3.1.

 

As the disclosure of cases of acting in concert may vary due to the specific circumstances (e.g. same or different total positions of the parties, entering or exiting of acting in concert by a single party) the standard form does not provide for a specific method how to notify cases of acting in concert.

 

In relation to the transactions referred to in DTR5.2.1 (b) to (h), the following list is provided as indication of the persons who should be mentioned:

 

- in the circumstances foreseen in DTR5.2.1 (b), the natural person or legal entity that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights;

 

- in the circumstances foreseen in DTR5.2.1 (c), the natural person or legal entity holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and natural person or legal entity lodging the collateral under these conditions;

 

- in the circumstances foreseen in DTR5.2.1 (d), the natural person or legal entity who has a life interest in shares if that person or entity is entitled to exercise the voting rights attached to the shares and the natural person or legal entity who is disposing of the voting rights when the life interest is created;

 

- in the circumstances foreseen in DTR5.2.1 (e), the controlling natural person or legal entity and, provided it has a notification duty at an individual level under DTR 5.1, under DTR5.2.1 (a) to (d) or under a combination of any of those situations, the controlled undertaking;

 

- in the circumstances foreseen in DTR5.2.1 (f), the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion;

 

- in the circumstances foreseen in DTR5.2.1 (g), the natural person or legal entity that controls the voting rights;

 

- in the circumstances foreseen in DTR5.2.1 (h), the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion (e.g. management companies).

 

v Applicable in the cases provided for in DTR5.2.1 (b) to (h). This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to DTR5.2 unless the percentage of voting rights held by the shareholder is lower than the lowest notifiable threshold for the disclosure of voting rights holdings in accordance with national practices (e.g. identification of funds managed by management companies).

 

vi The date on which threshold is crossed or reached should be the date on which the acquisition or disposal took place or the other reason triggered the notification obligation. For passive crossings, the date when the corporate event took effect.

 

vii The total number of voting rights held in the issuer shall be composed of all the shares, including depository receipts representing shares, to which voting rights are attached even if the exercise thereof is suspended.

 

viii If the holding has fallen below the lowest applicable threshold, please note that it might not be necessary to disclose the extent of the holding, only that the new holding is below that threshold.

 

ix In case of combined holdings of shares with voting rights attached "direct holding" and voting rights "indirect holding", please split the voting rights number and percentage into the direct and indirect columns - if there is no combined holdings, please leave the relevant box blank.

 

x Date of maturity/expiration of the financial instrument i.e. the date when right to acquire shares ends.

 

xi If the financial instrument has such a period - please specify this period - for example once every 3 months starting from [date].

 

xii In case of cash settled instruments the number and percentages of voting rights is to be presented on a delta-adjusted basis (DTR 5.3.3.A).

 

xiii If the person subject to the notification obligation is either controlled and/or does control another undertaking then the second option applies.

 

xiv The full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity has to be presented also in the cases, in which only on subsidiary level a threshold is crossed or reached and the subsidiary undertaking discloses the notification as only in this way will the markets get always the full picture of the group holdings. In case of multiple chains through which the voting rights and/or financial instruments are effectively held the chains have to be presented chain by chain by numbering each chain accordingly. Please see the below example: 

Name of ultimate controlling person A (chain 1)

Name of controlled undertaking B

Name of controlled undertaking C

Name of ultimate controlling person A (chain 2)

Name of controlled undertaking B

Name of controlled undertaking D

Name of ultimate controlling person A (chain3)

Name of controlled undertaking E

Name of controlled undertaking F

 

xv The names of controlled undertakings through which the voting rights and/or financial instruments are effectively held have to be presented irrespectively whether the controlled undertakings cross or reach the lowest applicable threshold themselves.

 

xvi Example: Correction of a previous notification.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUVONROKUWAAR
Date   Source Headline
13th Apr 20261:08 pmRNSResult of General Meeting
31st Mar 20267:00 amRNSResult of Retail Offer and Posting of Notice of GM
26th Mar 20267:05 amRNSRetail Offer to raise up to £0.5 million
26th Mar 20267:00 amRNSResults of Placing
25th Mar 20267:10 amRNSInterim Results and Notice of Investor Webinar
25th Mar 20267:00 amRNSProposed Placing, Subscription and Retail Offer
18th Mar 20267:00 amRNSLaunch of targeted radiopharmaceutical programme
10th Mar 20263:26 pmRNSBlock Listing Interim Review
17th Feb 20267:00 amRNS-RTechnical Feasibility for Pathogen Detector
11th Feb 20267:00 amRNSOptimer® Technology in Launched Library Prep Kit
29th Jan 20267:00 amRNSContract wins and first cash licensing receipts
7th Jan 20264:04 pmRNSTrading update - Media comment and speculation
7th Jan 20267:00 amRNSHalf Year Trading Update
23rd Dec 20257:00 amRNSAptamer signs licensing agreement with Alphazyme
23rd Dec 20257:00 amRNSAptamer signs licensing agreement with Alphazyme
16th Dec 202510:34 amRNSLicensing agreement with Twist Bioscience
27th Nov 20251:01 pmRNSResults of 2025 Annual General Meeting
27th Nov 20257:00 amRNSAGM Statement
14th Nov 20257:00 amRNSStrong contract wins build commercial momentum
4th Nov 20257:00 amRNSNew contract with top five pharma company
3rd Nov 20257:00 amRNSPosting of Annual Report and Notice of AGM
14th Oct 20257:00 amRNSFull Year Results for the 12mths to 30 June 2025
13th Oct 20257:00 amRNSNew contract with top 10 pharma
10th Oct 20257:00 amRNSNotice of Results, Analyst & Investor Presentation
8th Oct 20257:00 amRNSMajor top 3 global pharma contract win
26th Sep 20257:00 amRNS-RInvestor Event and Presentation
11th Sep 20257:00 amRNS-RNew contract with Metir plc
9th Sep 20257:00 amRNSNotification of dealings by a director/PDMR
2nd Sep 20257:00 amRNSTherapeutic development agreement with Invizius
28th Aug 20257:00 amRNSBlock Listing Interim Review
27th Aug 20257:00 amRNSBiomarker Discovery Service Launch
22nd Aug 20257:00 amRNSUpdate on licensing and development progress
19th Aug 20257:00 amRNSExercise of warrants
18th Aug 20253:44 pmRNSHolding(s) in Company
18th Aug 20257:00 amRNSContract extension with global pharma partner
8th Aug 20257:00 amRNS-RInvestor Technical Webinar
7th Aug 20255:24 pmRNSHolding(s) in Company
5th Aug 20258:05 amRNSHolding(s) in Company
31st Jul 20251:29 pmRNS-RInvestor Webinar
31st Jul 20257:00 amRNSTrading Update
28th Jul 202512:25 pmRNSHolding(s) in Company
24th Jul 202511:48 amRNSResult of General Meeting
21st Jul 20257:00 amRNSAdditional work commissioned by Unilever
18th Jul 20257:00 amRNSIssue of Equity in lieu of Non-Exec Director Fees
9th Jul 20252:53 pmRNSHolding(s) in Company
8th Jul 20257:00 amRNSPosting of Circular and Notice of General Meeting
4th Jul 20257:00 amRNSPlacing to raise £2.0 million
30th Jun 20257:00 amRNSLiver fibrosis breakthrough with Optimer® platform
25th Jun 20257:00 amRNSAgreement with global life sciences leader
30th May 20257:00 amRNSUnilever second Optimer development programme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.